

CITATION REPORT

List of articles citing

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial

DOI: 10.7326/m20-4207

Annals of Internal Medicine, 2020, 173, 623-631.

Source: <https://exaly.com/paper-pdf/75787244/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
396	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. 2020 , 7, 546		5
395	Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. 2020 , 32, 106116		1
394	Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. 2020 , 9,		9
393	Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in". 2020 , 11, 2132		50
392	The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak. 2020 , 7, 552991		
391	Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. 2020 , 63, 101942		39
390	Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. 2020 , 396, 1310-1311		10
389	Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. 2020 , 40, 1072-1081		9
388	Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. <i>International Journal of Infectious Diseases</i> , 2020 , 101, 107-120	10.5	5
387	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. 2020 , 38, 100776		20
386	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. 2020 , 25,		2
385	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. 2020 , 29, 100645		34
384	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. 2020 , 7, ofaa500		26
383	Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. <i>Annals of Internal Medicine</i> , 2020 , 173, W128-W129	8	12
382	Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. <i>Annals of Internal Medicine</i> , 2020 , 173, W156-W157	8	17
381	The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale. <i>Annals of Internal Medicine</i> , 2020 , 173, 662-663	8	7
380	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. 2020 , 9,		6

379	Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. 2020 , 6,	0
378	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. 2020 , 88, 106885	20
377	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. 2020 , 10, 1514-1527	80
376	Drug treatments for covid-19: living systematic review and network meta-analysis. <i>BMJ, The</i> , 2020 , 370, m2980	5.9 331
375	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. 2020 , 10,	4
374	A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19-A Call for Clinical Trials. 2020 , 7, ofaa350	19
373	Response to: 'Correspondence on ': hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef ' by Lo. 2020 ,	1
372	COVID-19-Lessons Learned and Questions Remaining. 2021 , 72, 2225-2240	34
371	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. 2020 , 60, 840-851	18
370	Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian. 2020 ,	3
369	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2020 , 17, e1003293	36
368	The Model for Early Covid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak. 2020 , 10,	20
367	Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019. 2020 , 11, 1330	
366	Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review. 2020 , 196, 1086-1093	13
365	Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. 2020 , 6, 1-9	37
364	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. 2020 , 12,	32
363	Mining twitter to explore the emergence of COVID-19 symptoms. 2020 , 37, 934-940	11
362	Azithromycin for severe COVID-19. 2020 , 396, 936-937	42

361	[Health crisis and reflexive crisis: The medical perspective in times of epidemic]. 2020 , 41, 507-509	1
360	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
359	It is time to drop hydroxychloroquine from our COVID-19 armamentarium. 2020 , 144, 110198	5
358	Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications. 2020 , 2, 760-766	7
357	Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review. 2020 , 11, 572168	8
356	A Note From the Editors. 2020 , 189, 1215-1217	1
355	Mild or Moderate Covid-19. 2020 , 383, 1757-1766	627
354	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. <i>International Journal of Infectious Diseases</i> , 2021 , 102, 110-114	10.5 3
353	How useful is serology for COVID-19?. <i>International Journal of Infectious Diseases</i> , 2021 , 102, 170-171	10.5 6
352	Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. 2021 , 3, e19-e27	28
351	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. 2021 , 890, 173717	14
350	Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. 2021 , 72, e844-e847	2
349	Reply to Million et al. 2021 , 72, e440-e441	
348	Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. 2021 , 76, 30-42	70
347	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. 2021 , 72, e835-e843	59
346	Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 138-140	9.5 8
345	Hydroxychloroquine with or without Azithromycin in Covid-19. 2021 , 384, 190	
344	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. 2021 , 133, 111008	14

343	Combining Antivirals and Immunomodulators to Fight COVID-19. 2021 , 42, 31-44		21
342	COVID-19: A review of therapeutic strategies and vaccine candidates. 2021 , 222, 108634		109
341	Hydroxychloroquine in the prevention of COVID-19 mortality. 2021 , 3, e2-e3		18
340	Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 134-135	9.5	0
339	Zoonotic coronavirus epidemics: Severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019. 2021 , 126, 321-337		6
338	Reporting and design of randomized controlled trials for COVID-19: A systematic review. 2021 , 101, 106239		1
337	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. 2021 , 232, 13-36		26
336	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of , , and clinical trials. 2021 , 11, 1207-1231		17
335	COVID-19 and Solid Organ Transplantation: A Review Article. 2021 , 105, 37-55		111
334	COVID-19: Clouds Over the Antimicrobial Resistance Landscape. 2021 , 52, 123-126		9
333	Rational for meta-analysis and randomized treatment: the COVID-19 example. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 6-8	9.5	4
332	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 2021 , 53, 117-134		26
331	COVID-19 in transplant recipients: The Spanish experience. 2021 , 21, 1825-1837		62
330	Has the door closed on hydroxychloroquine for SARS-COV-2?. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 3-5	9.5	3
329	Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19. 2021 , 190, 491-495		5
328	Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen. 2021 , 324, 242-248		12
327	Pregnancy and COVID-19: pharmacologic considerations. 2021 , 57, 195-203		23
326	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 19-27	9.5	144

325	Lines of Treatment of COVID-19 Infection. 2021 , 91-144		1
324	A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic. 2021 , 67, 134-138		1
323	Bots and Misinformation Spread on Social Media: Implications for COVID-19. 2021 , 23, e26933		23
322	Let's do better: public representations of COVID-19 science. 2021 , 6, 403-423		7
321	Japanese Rapid/Living recommendations on drug management for COVID-19. 2021 , 8, e664		6
320	COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home. <i>Tohoku Journal of Experimental Medicine</i> , 2021 , 255, 61-69	2.4	0
319	Actualizaci3n del manejo cl3nico de COVID-19 en pediatria: a un a2o de pandemia. 2021 , 88, 31-45		2
318	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. 2021 , 28,		11
317	Disentangling the association of hydroxychloroquine treatment with mortality in Covid-19 hospitalized patients through Hierarchical Clustering.		1
316	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. <i>Journal of Medical Virology</i> , 2021 , 93, 2694-2704	19.7	9
315	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. 2021 ,		28
314	Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial.		2
313	Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. 2021 ,		21
312	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. 2020 , 11, 583914		4
311	COVID-19 and the generation of novel scientific knowledge: Research questions and study designs. 2021 , 27, 694-707		1
310	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. 2021 , 16, 165-183		
309	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. 2021 , 2, CD013587		57
308	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). 2021 , 22, 1127-1141		3

307	Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management. 2021 , 65,		
306	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. 2021 ,	19	
305	Examining reporting and representation of patients with cancer in COVID-19 clinical trials. 2021 , 4, e1355	0	
304	TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection. 2020 , 11, 622614	24	
303	The Rheumatology Drugs for COVID-19 Management: Which and When?. 2021 , 10,	8	
302	Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. 2021 , 15, 510	1	
301	Balancing Healthcare and Economy Amidst the COVID-19 Pandemic: An Indian Experience. 2021 , 14, 827-833	3	
300	Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. 2021 , 115, 139-150	10	
299	Assessment of the Temporal Trajectory of Clinical Trials for COVID-19 Interventions After Highly Publicized Lay and Medical Attention. <i>JAMA Network Open</i> , 2021 , 4, e210689	10.4	0
298	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2021 , 174, 432-433	8	
297	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2021 , 174, 433-434	8	
296	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. 2021 , 35, 101658	2	
295	Prone positioning for severe ARDS in a postpartum COVID-19 patient following caesarean section. 2021 , 14,	2	
294	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. 2021 , 12, 607408	10	
293	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 441-451	10.5	10
292	Clinically applicable approach for predicting mechanical ventilation in patients with COVID-19. 2021 , 126, 578-589	6	
291	A Retrospective Analysis of the Impact of the Coronavirus Disease 2019 Pandemic on Health Care Workers in a Tertiary Hospital in Turkey. 2021 , 47, 948-954		
290	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. 2021 , 397, 1063-1074	105	

289	Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. 2021 , 22, 947-952		1
288	Correction: Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2021 , 174, 435	8	1
287	Current evidence for COVID-19 therapies: a systematic literature review. 2021 , 30,		11
286	Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies. 2021 , 31, e2228		4
285	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2021 , 174, 434	8	4
284	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. 2021 , 22, 1257-1266		4
283	Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2021 , 16, e0248132		20
282	Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms. 2021 , 15, 1213-1223		0
281	COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact.		1
280	Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective. 2021 , 110, 1002-1017		5
279	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. 2021 , 57,		76
278	Inflammatory, but not respiratory symptoms, associated with ongoing upper airway viral replication in outpatients with uncomplicated COVID-19.		
277	Characteristics of Patients With Immune-Mediated Inflammatory Diseases Hospitalized for SARS-CoV-2 Infection. 2021 ,		
276	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021 , 27, 389-395	9.5	19
275	The first 12 months of COVID-19: a timeline of immunological insights. 2021 , 21, 245-256		140
274	QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. 2021 , 30, 694-706		13
273	Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2. 2021 , 13,		3
272	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. <i>Therapeutics and Clinical Risk Management</i> , 2021 , 17, 371-387	2.9	31

271	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e216468	10.4	50
270	Neutralizing Antibody Therapeutics for COVID-19. 2021 , 13,		44
269	Perspectives on Virtual (Remote) Clinical Trials as the "New Normal" to Accelerate Drug Development. 2021 ,		3
268	COVID-19: Antiviral Tedavi.		
267	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. 2021 , 23, 28		7
266	Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial.		10
265	Spike Protein Targeting Nano-Glue That Captures and Promotes SARS-CoV-2 Elimination.		0
264	Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment. 147775092110114		0
263	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. 2021 , 60, SI25-SI36		5
262	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. 2021 , 9, E693-E702		7
261	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. 2021 , 12, 2349		83
260	A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. 2021 , 21, 675-686		8
259	The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis. 2021 , 39, 159-170		4
258	How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols. 2021 , 8, ofab072		4
257	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. 2021 , 8, 681-691		2
256	The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review. 2021 , 151, 1854-1878		24
255	COVID-19: breaking down a global health crisis. 2021 , 20, 35		43
254	The Course of COVID-19 in Four Patients with HIV During the Pandemic. 2021 , 19, 286-291		0

253	Therapeutic strategies to fight COVID-19: Which is the status artis?. 2021 ,	12
252	Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. 2021 , 49, 3000605211013550	35
251	Unproven Therapy Algorithms for Early SARS-CoV-2 Infection Are Dangerous. 2021 , 134, e345	
250	Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis. 2021 , 126, 524-534	11
249	Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study. 2021 , 53, 1187-1193	4
248	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. 2021 , 7, 1001-1008	8
247	Correlation of the rise and fall in COVID-19 cases with the social isolation index and early outpatient treatment with hydroxychloroquine and chloroquine in the state of Santa Catarina, southern Brazil: A retrospective analysis. 2021 , 41, 102005	1
246	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. 2021 , 238, 569-578	0
245	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. 2021 , 14, 601-621	29
244	Therapeutic Agents Against COVID-19 with Clinical Evidence. 2021 , 27, 1608-1617	1
243	Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. 2021 , 14, 1101-1112	4
242	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. 2021 , 84, 1254-1268	42
241	Complementary and alternative medicines use in COVID-19: A global perspective on practice, policy and research. 2021 ,	11
240	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. 2021 , 151, 112106	3
239	Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19. 2021 , 46, 1308-1311	1
238	Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. 2021 , 19, 68	2
237	Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights. 2021 , 14, 715-734	1
236	Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk. <i>BMJ Open</i> , 2021 , 11, e046799	3 2

235	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. 2021 , 115, 456-466	5
234	A scheme for inferring viral-host associations based on codon usage patterns identifies the most affected signaling pathways during COVID-19. 2021 , 118, 103801	5
233	Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial. 2021 , 22, 915	7
232	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. 2021 , 18, 261-270	2
231	Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions. 2021 , 44, 408-421	12
230	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.	
229	Analytical Methodologies for Determination of Hydroxychloroquine and Its Metabolites in Pharmaceutical, Biological and Environmental Samples. 2021 , 17,	0
228	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. 2021 , 2021, 5556207	2
227	[SARS-CoV-2 infection: Available data on 15th April 2021]. 2021 , 38, 616-625	
226	Evidence-based approach to early outpatient treatment of SARS-CoV-2 (COVID-19) infection. 2021 , 34, 464-468	1
225	Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis. 2021 , 27, 882-889	10
224	SARS-CoV-2 Antiviral Therapy. 2021 , e0010921	12
223	Advances in the computational landscape for repurposed drugs against COVID-19. 2021 , 26, 2800-2815	4
222	Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. 2021 , 96, 107636	6
221	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. 2021 , 76, 285-295	3
220	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. 2021 , 19, 1219-1244	3
219	Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis. 2021 , e2276	2
218	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2021 , 10, 1837-1885	10

217	Clinical presentation, outcomes and factors associated with mortality: A prospective study from three COVID-19 referral care centres in West Africa. <i>International Journal of Infectious Diseases</i> , 2021 , 108, 45-52	10.5	3
216	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. 2021 , 2021, 1-22		0
215	Concerning Pathophysiology and Justifying Clinical Trials. 2021 , 134, e439		0
214	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. 2021 , 1		3
213	Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. 2021 , 30, 1493-1503		2
212	Triangle of cytokine storm, central nervous system involvement, and viral infection in COVID-19: the role of sFasL and neuropilin-1. 2021 ,		4
211	Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. 2021 , 19, 317-326		5
210	India and management of COVID-19: A case study on published guidelines. 2021 , 15, 171-179		
209	Comprehensive analysis of SARS-COV-2 drug targets and pharmacological aspects in treating the COVID-19. 2021 ,		2
208	Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis. 2021 , 73, 1589-1600		3
207	Remdesivir and Mortality in Patients with COVID-19. 2021 ,		5
206	Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. 2021 , 38, 100993		13
205	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <i>Journal of Medical Virology</i> , 2021 , 93, 6737-6749	19.7	4
204	Antirheumatic drugs and COVID-19: frustrations and hopes. 2021 , 134-139		
203	QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine. 2022 , 23, e21-e23		0
202	Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display.		
201	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. <i>The Lancet Regional Health Americas</i> , 2021 , 2, 100062		9
200	Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1124-1130	9.5	18

199	Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial.		0
198	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. 2021 , 43, 102135		4
197	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. 2021 , 398, 843-855		61
196	. 2021 ,		0
195	COVID-19: Pulmonary and Extra Pulmonary Manifestations. 2021 , 9, 711616		10
194	Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. 2021 , 9, 1010-1020		17
193	Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. 2021 , 13, 21866-21902		7
192	Bibliography. 2021 , 283-307		
191	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. 2021 , 9, 729559		7
190	Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial. 2021 , 61, 102769		10
189	Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19. 2021 ,		3
188	Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. 2021 , 21, 986		5
187	A hitchhiker's guide through the COVID-19 galaxy. 2021 , 232, 108849		0
186	Characteristics of patients with immune-mediated inflammatory diseases hospitalized for SARS-CoV-2 infection. 2021 ,		
185	Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin. <i>Journal of Clinical Epidemiology</i> , 2021 , 107-120	5-7	4
184	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. <i>Journal of Clinical Epidemiology</i> , 2021 , 139, 68-79	5-7	3
183	Mesenchymal stem cells in SARS-CoV-2 infection: A hype or hope. 2021 , 284, 119901		1
182	Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases. 2021 , 88, 105226		3

181	Experimental Pharmacotherapy for COVID-19: The Latest Advances. 2021 , 13, 1-13		14
180	Antimalarial drugs (and lupus). 2021 , 601-609		
179	Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. 2021 , 2, 100026		4
178	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. <i>BMC Infectious Diseases</i> , 2021 , 21, 72	4	19
177	Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. 2021 , 33, 129-135		1
176	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. 2021 , 21, 5		4
175	COVID-19: What Do Rheumatologists Need to Know?. 2021 , 23, 5		3
174	High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration. 2021 , 16, e0246396		2
173	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. 2021 , 53, 166-219		11
172	Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19. 2021 , 379-416		7
171	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. 2020 , 15, 1501-1506		18
170	Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. 2020 ,		2
169	Therapeutics for COVID-19: established and in development. 2020 , 41, 217		2
168	Natural history of COVID-19 and therapeutic options. 2020 , 16, 1159-1184		41
167	Bringing evidence from press release to the clinic in the era of COVID-19. 2021 , 76, 547-549		2
166	Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility. 2020 , 27, e573-e583		3
165	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study.		7
164	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.		7

163	Factors associated with the spatial heterogeneity of COVID-19 in France: a nationwide ecological study.	0
162	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. 2020 ,	17
161	Could nutrition modulate COVID-19 susceptibility and severity of disease? A systematic review.	8
160	A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19.	4
159	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients.	2
158	Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials.	3
157	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).	2
156	Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data.	2
155	A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.	3
154	Potent anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L. 2020 ,	9
153	Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. 2020 , 17, e1003501	78
152	[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "Bromhexine and Spironolactone for Coronavirus Infection requiring hospitalization (BISCUIT)". 2020 , 60, 4-15	7
151	Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial. 2020 ,	6
150	Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study. 2020 ,	15
149	The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries. 2020 , 13, 4577-4587	6
148	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. 2020 , 13, 4673-4695	20
147	Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19. 2020 , 65, 27-30	8
146	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. 2020 , 103, 1635-1639	77

145	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. 2020 ,	3
144	Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo. 2020 , 103, 2419-2428	46
143	The predictive role of lymphocyte subsets and laboratory measurements in COVID-19 disease: a retrospective study. 2021 , 15, 17534666211049739	1
142	HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis. 2021 , 11, 59-70	1
141	The Features of Pathobiology and Clinical translation of Approved treatments for Coronavirus Disease 2019 (COVID-19). 2021 ,	1
140	Emergence of Ethnomedical COVID-19 Treatment: A Literature Review. 2021 , 14, 4277-4289	1
139	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. 2021 ,	0
138	Preventing disease after exposure to COVID-19 using hydroxychloroquine: A summary of a protocol for exploratory re-analysis of age and time-nuanced effects.	2
137	Review of current clinical management guidelines for COVID-19 with special reference to India. 2020 , 14, 171-176	3
136	Representativeness of Racial and Ethnic Groups in COVID-19 Outpatient Trials in the United States.. 2022 , 97, 184-186	0
135	Outcomes of COVID-19 Patients Hospitalized at Acute Care Services: Real-World Experience in the New York Metropolitan Area During the Early Pandemic Before Initiation of Clinical Trials. 2021 , 29, e88-e96	
134	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein using mRNA Display.	
133	Current evidence for COVID-19 therapies: a systematic literature review.	
132	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.	
131	A Systematic Review and Network Meta-Analysis for COVID-19 Treatments.	
130	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. 2021 , 8, ofaa602	3
129	Reply to Neves. 2021 , 73, e1772-e1774	2
128	Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials. 2020 , 20, 350-357	

127	COVID-19-Practicing Prevention in the Workplace. 2020 , 24, 133-136		4
126	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. 2021 , 10, 294		0
125	Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. <i>BMJ, The</i> , 2021 , 375, e068060	5.9	9
124	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. 2021 ,		4
123	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis.		1
122	Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysis.		
121	Clinical Trials in COVID-19 Management & Prevention: A Meta-epidemiological Study examining methodological quality.		
120	Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study.		
119	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. 2021 , 11, 93-107		9
118	Management of symptomatic patients with suspected mild-moderate COVID-19 in general practice. What was published within the first year of the pandemic? A scoping review. 2021 , 27, 339-345		0
117	Treatment and therapeutic agents. 2022 , 121-176		
116	Negacionismo religioso: Bolsonaro e lideranças evangélicas na pandemia Covid-19. 2021 , 41, 49-74		1
115	Current Updates on Covid-19 Vaccine Research and an Overview of Therapeutic Drug Research. 2021 , 18, 439-457		
114	Inflammatory but not respiratory symptoms are associated with ongoing upper airway viral shedding in outpatients with uncomplicated COVID-19.. 2021 , 102, 115612		1
113	ESCMID COVID-19 Living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	16
112	Decision-making in the midst of uncertainty: appraising expensive medicines in England. 2021 , 26, 5523-5531		
111	Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India.. 2021 , 13, e19976		0
110	Many Trials of Hydroxychloroquine for SARS-CoV-2 Were Redundant and Potentially Unethical: An Analysis of the NIH Clinical Trials Registry. <i>Journal of Clinical Epidemiology</i> , 2021 ,	5.7	0

109	A Narrative Review of Existing Options for COVID-19-Specific Treatments. 2021 , 2021, 8554192	
108	Photo-mediated and advanced oxidative processes applied for the treatment of effluents with drugs used for the treatment of early COVID-19: Review. 2021 , 6, 100140	0
107	Risk factors for delirium among SARS-CoV-2 positive veterans.. 2021 , 309, 114375	
106	COVID-19 Health Information on Google: A QUEST Cross-Sectional Quality and Readability Analysis.. 2022 ,	0
105	Technical procedures and REDCap tools for internet-based clinical trials.. 2022 , 106660	0
104	Clinical pharmacology: Current innovations and future challenges.. 2021 ,	0
103	High-cited favorable studies for COVID-19 treatments ineffective in large trials.	
102	COVID-19: les thérapeutiques. 2022 , 1, 13-13	
101	Pulmonary Aspects of COVID-19.. 2022 , 73, 81-93	2
100	Outpatient Therapies for COVID-19: How Do We Choose?. 2022 , 9, ofac008	3
99	Safety profile of COVID-19 drugs in a real clinical setting.. 2022 , 1	3
98	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. 2022 ,	1
97	Hydroxychloroquine for COVID-19: Variation in Regional Political Preferences Predicted New Prescriptions after President Trump's Endorsement.. 2022 ,	0
96	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients [A Systematic Review.	0
95	Systematic Review and Meta-Analysis of Ivermectin for Treatment of COVID-19: Evidence Beyond the Hype. <i>SSRN Electronic Journal</i> ,	1
94	Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.. <i>International Journal of Infectious Diseases</i> , 2021 ,	10.5 0
93	Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environment.. <i>Science of the Total Environment</i> , 2022 , 820, 153122	10.2 0
92	Outpatient therapies for COVID-19: How do we choose?.	

91	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021 , 23, 28	3.9	2
90	Antiviral cyclic peptides targeting the main protease of SARS-CoV-2.. <i>Chemical Science</i> , 2022 , 13, 3826-3836	9.4	2
89	Acute management of COVID-19 in the emergency department: An evidence-based review.. <i>Journal of Family Medicine and Primary Care</i> , 2022 , 11, 424-433	1.5	0
88	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.. <i>European Journal of Clinical Investigation</i> , 2022 , e13763	4.6	1
87	Rationale and Design of the COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V) Randomized Clinical Trial: Hydroxychloroquine vs. Placebo in Non-Hospitalized Patients.. <i>Arquivos Brasileiros De Cardiologia</i> , 2022 , 118, 378-387	1.2	1
86	Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study.. <i>BMJ Open</i> , 2022 , 12, e055137	3	1
85	NF- κ B Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders?. <i>Biology</i> , 2022 , 11,	4.9	0
84	Impact of COVID-19 and malaria Coinfection on Clinical Outcomes: A Retrospective Cohort Study.. <i>Clinical Microbiology and Infection</i> , 2022 ,	9.5	1
83	Can anti-parasitic drugs help control COVID-19?. <i>Future Virology</i> , 2022 ,	2.4	1
82	Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine.. <i>Journal of Medical Virology</i> , 2022 ,	19.7	
81	Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers.		1
80	The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19.. <i>JAMA Network Open</i> , 2022 , 5, e222973	10.4	3
79	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.. <i>BMJ Open</i> , 2022 , 12, e048502	3	3
78	Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial.. <i>British Journal of General Practice</i> , 2022 ,	1.6	5
77	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. <i>Journal of Clinical Epidemiology</i> , 2022 ,	5.7	1
76	Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis.. <i>JAMA Network Open</i> , 2022 , 5, e226269	10.4	3
75	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.. <i>Infection, Genetics and Evolution</i> , 2022 , 99, 105254	4.5	2
74	Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial.. <i>Trials</i> , 2022 , 23, 273	2.8	

73	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.. <i>The Lancet Regional Health Americas</i> , 2022 , 11, 100243		0
72	Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis.		1
71	Randomised clinical trials on outpatient treatment of SARS-COV-2 infection: Light and shadows.. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14896	2.9	1
70	Implementation of a fully remote randomized clinical trial with cardiac monitoring. <i>Communications Medicine</i> , 2021 , 1,		0
69	Artemisinin Yield and Cyto/Genotoxic Properties of Naturally Grown Artemisia Annua L. in Uludag, Turkey. <i>Journal of Innovative Science and Engineering (JISE)</i> ,	0.2	
68	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
67	Update on Retinal Drug Toxicities.. <i>Current Ophthalmology Reports</i> , 2021 , 9, 1-10	1.8	1
66	COVID-19 in Children: Update on Diagnosis and Management.. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021 , 42, 737-746	3.9	
65	Efficacy and Safety of Fixed Combination of Hydroxychloroquine with Azithromycin Versus Hydroxychloroquine and Placebo in Patients with Mild COVID-19: Randomized, double blind, Placebo controlled trial[]		
64	Design, Synthesis, and Development of 4-[(7-Chloroquinoline-4-yl)amino]phenol as a Potential SARS-CoV-2 Mpro Inhibitor. <i>ChemistrySelect</i> , 2022 , 7,	1.8	0
63	Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.. <i>Revista Brasileira De Terapia Intensiva</i> , 2022 , 33, 487-536	1.2	
62	Pharmacological Management. 2022 , 67-96		
61	Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic.. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022 ,	1.6	0
60	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. <i>Anti-Infective Agents</i> , 2022 , 20,	0.6	
59	Being a Public Health Statistician During a Global Pandemic. <i>Statistical Science</i> , 2022 , 37,	2.4	0
58	Clinical and Laboratory Differences Between Delta and UK Variants of SARS-CoV-2: B.1.617.2 and B.1.1.7. <i>Tohoku Journal of Experimental Medicine</i> , 2022 ,	2.4	
57	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1
56	Effective antiviral regimens to reduce COVID-19 hospitalizations: a systematic comparison of randomized controlled trials.		0

55	The ethical limits of physicians' autonomy and the Brazilian Federal Council of Medicine. <i>Cadernos De Saude Publica</i> , 2022 , 38,	3.2	
54	Management of Acute Respiratory Distress Syndrome in COVID-19 Patients. <i>Acta Anaesthesiologica Belgica</i> , 2022 , 73, 5-14		
53	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. <i>Therapeutics and Clinical Risk Management</i> , Volume 18, 603-617	2.9	0
52	Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.		0
51	Covid-19: Doctor who sold hydroxychloroquine as 'magic bullet' treatment is jailed. <i>BMJ, The</i> , 01395	5.9	
50	Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022 , 40, 289-295	0.1	
49	Mortality and risk factors for COVID-19 in hemodialysis patients: A systematic review and meta-analysis. <i>Science Progress</i> , 2022 , 105, 003685042211108	1.1	0
48	Leveraging Real-World Data in COVID-19 Response. <i>Statistics in Biopharmaceutical Research</i> , 1-33	1.2	
47	Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.		
46	Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. <i>BMC Infectious Diseases</i> , 2022 , 22,	4	1
45	Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. 2022 , 387, 599-610		13
44	Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.		
43	Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. 2022 ,		2
42	Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies. 106002802211135		0
41	A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination.		3
40	Pre-hospital Management of COVID-19: Looking for a Future Perspective. 2022 , 395-419		0
39	Effect of Hydroxychloroquine, Favipiravir, Lopinavir/Ritonavir, Remdesivir, Umifenovir, and Interferon beta-1a in Covid-19 patients: A systematic review of Randomized Clinical Trials. 2022 , 125, 366-372		0
38	Pela Ciência, contra os cientistas? Negacionismo e as disputas em torno das políticas de saúde durante a pandemia. 2022 , 24, 98-138		0

- 37 Outpatient Management of COVID-19: A Primer for the Dermatologist. ○
- 36 Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. **2022**, 12, 1456 ○
- 35 Effects of COVID-19 on Arrhythmia. **2022**, 9, 292 ○
- 34 Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS. **2022**, 29, ○
- 33 Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. 1-21 1
- 32 Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. **2022**, 17, e0273526 ○
- 31 Care for adults with COVID -19: living guidelines from the National COVID -19 Clinical Evidence Taskforce. **2022**, 217, 368-378 1
- 30 COVID-19: Lesson Learnt from Diagnostics to Therapeutics. **2022**, 345-374 ○
- 29 Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. **2022**, 16, 175346662211327 ○
- 28 Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. ○
- 27 The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis. **2022**, 5, 1
- 26 Tissue- and cell-expression of druggable host proteins provide insights into repurposing drugs for COVID -19. ○
- 25 Critical appraisal of medical literature in undergraduate and postgraduate medical students. 7, ○
- 24 Distribution of age, sex, race, and ethnicity in COVID-19 clinical drug trials in the United States: A review. **2022**, 123, 106997 ○
- 23 Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. **2022**, 20, 1
- 22 Efficacy and safety of add-on Viola odorata L. in the treatment of COVID-19: A randomized double-blind controlled trial. **2023**, 304, 116058 ○
- 21 COVID-19 pandemic: the impact on Canada's intensive care units. **2022**, 7, 1411-1472 ○
- 20 Hydroxychloroquine is metabolized by CYP2D6, CYP3A4, and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A4 in vitro. DMD-AR-2022-001018 ○

19	Hypertension related toxicity of chloroquine explains its failure against COVID-19: Based on rat model. 13,	0
18	Ethical issues of the off-label use of drugs for treatment of COVID-19. 2022 ,	0
17	Misinterpretation of statistical nonsignificance as a sign of potential bias: Hydroxychloroquine as a case study. 1-20	0
16	Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up..	1
15	Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19.	3
14	Clinical Characteristics in the Acute Phase of COVID-19 That Predict Long COVID: Tachycardia, Myalgias, Severity, and Use of Antibiotics as Main Risk Factors, While Education and Blood Group B Are Protective. 2023 , 11, 197	1
13	Hydroxychloroquine for treatment of non-hospitalized adults with COVID -19: A meta-analysis of individual participant data of randomized trials.	0
12	Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. 2023 , 99-139	0
11	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59,	0
10	The Democratic Virtues of Randomized Trials. 2022 ,	0
9	Pan-American Guidelines for the Treatment of SARS-CoV-2/COVID-19: A Joint Evidence-Based Guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API).	0
8	A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. 2023 , 11,	0
7	Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. 2023 , 42, 373-383	1
6	Inclusion in clinical research: cross-sectional study assessing potential barriers to informed consent in randomized controlled trials published in top general and internal medical journals.	0
5	Hidroxicloroquina para Pacientes com COVID-19 n Hospitalizados: Uma Revis Sistemica e Metanlise de Ensaios Clnicos Randomizados. 2023 , 120,	0
4	Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. 11, 2140-2159	0
3	Exploring the Link Between Malaria and COVID-19. 2023 , 311-338	0
2	Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective. 2023 , 18,	0

- 1 Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.

o